A randomized controlled trial to evaluate outcomes with Aggrenox in patients with SARS-CoV-2 infection.

However, for the day 28 linear regression model without lab values, treatment group was marginally significant in the full model (β = 0.86, p = 0.07) (S4 Table in S1 File ).

also in 26,082 other papers

Most of the patients who experienced respiratory failure were in the control group (Aggrenox: 4 vs control: 7), but these data failed to reach statistical significance on univariate analyses (p = 0.34).

also in 6,035 other papers

Conclusion In this study of hospitalized patients with COVID-19, while the outcomes of COVID illness severity, odds of mortality, and chance of respiratory failure were better in the Aggrenox group compared to standard of care alone, the data did not reach statistical significance to support the standard use of adjuvant Aggrenox in such patients. http://dx.doi.org/10.13039/100001003 Boehringer Ingelheim https://orcid.org/0000-0002-4162-4691 Singla Amit http://dx.doi.org/10.13039/100000002 National Institutes of Health UL1TR003017 Greenberg Patricia http://dx.doi.org/10.13039/100000002 National Institutes of Health NS065957 and NS103740 Boison Detlev This was an independent, investigator-initiated study supported by Boehringer Ingelheim Pharmaceuticals, Inc.

also in 111,027 other papers

Furthermore, while not statistically significant, Kaplan-Meier analyses visually suggest an increasing trend of later death in the control group as day 28 was approached ( Fig 2a–2c ).

also in 63,971 other papers